A Randomized, Open-label, Multicenter, Multi-arm, Phase 1b/2 Platform Study to Evaluate Safety and Efficacy of Investigational Immunotherapies in Participants With Previously Treated Unresectable or Metastatic Melanoma
Latest Information Update: 22 Nov 2022
At a glance
- Drugs IBI 110 (Primary) ; Sintilimab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Innovent Biologics
Most Recent Events
- 16 Nov 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Oct 2022 New trial record